Aethlon Medical and North Immunology Merge in All-Stock Transaction
3 reports, 3 independent
Updated Sep 17
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aethlon Medical, Inc. announced a definitive merger agreement for an all-stock transaction with North Immunology, Inc. The deal is concurrent with a private placement expected to raise approximately $180 million in gross proceeds. The combined company will operate as North Immunology and trade on the Nasdaq under the ticker symbol NRTX.
Why it matters
The merger combines Aethlon Medical's resources with North Immunology's lead program, NOR-101, a bispecific antibody targeting inflammation. The $180 million infusion of cash is intended to fund operations through the second half of 2028, supporting the drug's clinical trials.